Literature DB >> 10080930

Expression of CD30 ligand (CD153) on murine activated T cells.

O Shimozato1, K Takeda, H Yagita, K Okumura.   

Abstract

CD30, a member of the TNF receptor family, has been implicated in the activation of T cells and B cells. In the present study, we characterized the expression and function of murine CD30 ligand (mCD153) by utilizing mCD153 transfectants and a novel mAb against mCD153 (RM153), which can inhibit the binding of murine CD30 to mCD153. The mCD153 transfectants did not co-stimulate the proliferation of anti-CD3-stimulated naive T cells but enhanced the proliferation of anti-CD28-co-stimulated T cells. The mCD153 transfectants exhibited a potent co-stimulatory activity for proliferation of pre-activated T cells that expressed CD30 after anti-CD3 and anti-CD28 stimulation. In contrast to the CD30 expression on naive T cells that required anti-CD28 co-stimulation, mCD153 expression was observed on anti-CD3-stimulated T cells without the anti-CD28 co-stimulation, predominantly on CD4(+) T cells with a transient kinetics which peaked at 24 h but disappeared at 48 h. In contrast to the preferential expression of CD30 on Th2 cells, mCD153 was expressed on both Th1 and Th2 cells after anti-CD3 stimulation. These results indicated a differential regulation of CD30 and CD153 expression in T cells, which may be relevant to immuno-regulatory role of the CD30-CD153 interaction. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10080930     DOI: 10.1006/bbrc.1999.0336

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  13 in total

Review 1.  Deciphering CD30 ligand biology and its role in humoral immunity.

Authors:  Mary K Kennedy; Cynthia R Willis; Richard J Armitage
Journal:  Immunology       Date:  2006-06       Impact factor: 7.397

Review 2.  Bone marrow transplantation and approaches to avoid graft-versus-host disease (GVHD).

Authors:  Bruce R Blazar; William J Murphy
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-09-29       Impact factor: 6.237

3.  Multiple innate signaling pathways cooperate with CD40 to induce potent, CD70-dependent cellular immunity.

Authors:  Jennifer A McWilliams; Phillip J Sanchez; Catherine Haluszczak; Laurent Gapin; Ross M Kedl
Journal:  Vaccine       Date:  2009-12-06       Impact factor: 3.641

Review 4.  CD30: from basic research to cancer therapy.

Authors:  Hiromi Muta; Eckhard R Podack
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

5.  Critical roles of CD30/CD30L interactions in murine autoimmune diabetes.

Authors:  S Chakrabarty; M Nagata; H Yasuda; L Wen; M Nakayama; S A Chowdhury; K Yamada; Z Jin; R Kotani; H Moriyama; O Shimozato; H Yagita; K Yokono
Journal:  Clin Exp Immunol       Date:  2003-09       Impact factor: 4.330

6.  CD30 is required for activation of a unique subset of interleukin-17A-producing γδ T cells in innate immunity against Mycobacterium bovis Bacillus Calmette-Guerin infection.

Authors:  Ying Guo; Xun Sun; Kensuke Shibata; Hisakata Yamada; Hiromi Muta; Eckhard R Podack; Yasunobu Yoshikai
Journal:  Infect Immun       Date:  2013-08-05       Impact factor: 3.441

Review 7.  The role of costimulatory receptors of the tumour necrosis factor receptor family in atherosclerosis.

Authors:  Ricardo F Antunes; Juan Carlos Kaski; Ingrid E Dumitriu
Journal:  J Biomed Biotechnol       Date:  2011-12-22

8.  Critical contribution of OX40 ligand to T helper cell type 2 differentiation in experimental leishmaniasis.

Authors:  H Akiba; Y Miyahira; M Atsuta; K Takeda; C Nohara; T Futagawa; H Matsuda; T Aoki; H Yagita; K Okumura
Journal:  J Exp Med       Date:  2000-01-17       Impact factor: 14.307

9.  Evaluation of serum levels of sCD30L ligand in patients with ovarian cancer in terms of selected clinico-pathological factors.

Authors:  Anita Chudecka-Głaz; Izabella Rzepka-Górska
Journal:  Contemp Oncol (Pozn)       Date:  2013-01-04

10.  IL-17A-producing CD30(+) Vδ1 T cells drive inflammation-induced cancer progression.

Authors:  Yoshitaka Kimura; Nao Nagai; Naoki Tsunekawa; Marimo Sato-Matsushita; Takayuki Yoshimoto; Daniel J Cua; Yoichiro Iwakura; Hideo Yagita; Futoshi Okada; Hideaki Tahara; Ikuo Saiki; Tatsuro Irimura; Yoshihiro Hayakawa
Journal:  Cancer Sci       Date:  2016-09-01       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.